Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87%

Vanda Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 9.94 on March 10, 2026. This achievement marks a notable increase from its 52-week low of USD 3.81, reflecting a robust performance over the past year. The stock has demonstrated a remarkable 59.87% increase in value, significantly outperforming the S&P 500, which has seen a gain of 20.78% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology sector, Vanda Pharmaceuticals has a market capitalization of USD 340 million. Despite its loss-making status, the company maintains a price-to-book ratio of 1.04, indicating a valuation that may appeal to certain investors. The company's financial metrics, including a negative return on equity of -67.38% and a debt-to-equity ratio of -0.79, provide insight into its current financial health. This recent price movement highlights Vanda Pharmaceuticals' position within the market and its performance relative to broader industry trends.